Loan Receivable (Details) - USD ($) |
3 Months Ended | 9 Months Ended | 12 Months Ended | ||||||
|---|---|---|---|---|---|---|---|---|---|
Oct. 04, 2023 |
Sep. 30, 2024 |
Sep. 30, 2025 |
Sep. 30, 2024 |
Dec. 31, 2024 |
Dec. 31, 2023 |
Nov. 27, 2024 |
Aug. 02, 2024 |
Feb. 28, 2024 |
|
| Loan Receivable | |||||||||
| Outstanding balance of loan receivable | $ 3,668,500 | ||||||||
| Interest income | $ 34,481 | $ 76,589 | $ 79,037 | ||||||
| Liminatus Pharma, LLC | |||||||||
| Loan Receivable | |||||||||
| Outstanding balance of loan receivable | 3,669,000 | $ 819,000 | |||||||
| Interest income | 123,000 | 10,000 | |||||||
| Unsecured promissory note | Liminatus Pharma, LLC | |||||||||
| Loan Receivable | |||||||||
| Loan to Iris | $ 1,500,000 | $ 5,000,000 | $ 3,500,000 | $ 2,500,000 | |||||
| Period for note payable | 30 days | ||||||||
| Interest rate | 5.00% | ||||||||
| Outstanding balance of loan receivable | 3,700,000 | 800,000 | |||||||
| Interest income | $ 100,000 | ||||||||
| Unsecured promissory note | Maximum | Liminatus Pharma, LLC | |||||||||
| Loan Receivable | |||||||||
| Interest income | $ 100,000 | ||||||||